
Suspected Resistant Hypertension Pathway



* See Appendix 1, Table 3: Features of Secondary Hypertention

+ Spironolactone preferred over beta blocker if patient does not have hyperkalemia or severe renal impairment

‡ See Appendix 1, Table 1 for recommended dosing

References: 1.Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi:10.1161/HYP.000000000000084